Biotechnology Acquisitions in Iowa

Isoray, Inc. completed an all-stock merger with Viewpoint Molecular Targeting, effective February 3, 2023, combining Isoray's brachytherapy expertise with Viewpoint's radiopharmaceutical and diagnostic pipeline. Under the deal each Viewpoint share converted into 3.1642 shares of Isoray (totaling 136,545,075 shares, ~49% of Isoray's outstanding shares); Viewpoint CEO Thijs Spoor was named CEO of the combined company and outgoing Isoray CEO Lori Woods became Chair.

BigHat Biosciences has acquired Frugi Biotechnology to integrate Frugi's cell-free protein synthesis (CFPS) technology into BigHat's AI/ML-enabled drug discovery platform. The acquisition brings CFPS capabilities and Frugi's team in-house to help BigHat scale its antibody synthesis and discovery workflows; terms were not disclosed.